Steeve Provencher Selected Research

Monocrotaline

1/2022	Macrophage-NLRP3 Activation Promotes Right Ventricle Failure in Pulmonary Arterial Hypertension.
3/2021	Preclinical Investigation of Trifluoperazine as a Novel Therapeutic Agent for the Treatment of Pulmonary Arterial Hypertension.
1/2021	Oxidized DNA Precursors Cleanup by NUDT1 Contributes to Vascular Remodeling in Pulmonary Arterial Hypertension.
1/2021	17β-Estradiol and estrogen receptor α protect right ventricular function in pulmonary hypertension via BMPR2 and apelin.
10/2020	Identification of Long Noncoding RNA H19 as a New Biomarker and Therapeutic Target in Right Ventricular Failure in Pulmonary Arterial Hypertension.
1/2020	PIM1 (Moloney Murine Leukemia Provirus Integration Site) Inhibition Decreases the Nonhomologous End-Joining DNA Damage Repair Signaling Pathway in Pulmonary Hypertension.
1/2018	Loss of SMAD3 Promotes Vascular Remodeling in Pulmonary Arterial Hypertension via MRTF Disinhibition.
1/2018	Urocortin-2 improves right ventricular function and attenuates pulmonary arterial hypertension.
9/2015	miR-223 reverses experimental pulmonary arterial hypertension.
1/2015	A miR-208-Mef2 axis drives the decompensation of right ventricular function in pulmonary hypertension.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Steeve Provencher Research Topics

Disease

33	Pulmonary Arterial Hypertension 04/2022 - 05/2005
16	Pulmonary Hypertension 01/2022 - 04/2011
13	Neoplasms (Cancer) 10/2021 - 09/2012
12	Vascular Remodeling 03/2021 - 06/2014
8	Hypoxia (Hypoxemia) 01/2022 - 09/2012
8	Chronic Obstructive Pulmonary Disease (COPD) 01/2015 - 06/2010
7	Heart Failure 06/2019 - 03/2006
6	Hypertrophy 01/2022 - 01/2015
4	Fibrosis (Cirrhosis) 01/2022 - 01/2020
4	Vascular Diseases (Vascular Disease) 01/2022 - 08/2014
4	Inflammation (Inflammations) 01/2019 - 01/2013
4	Familial Primary Pulmonary Hypertension 09/2010 - 06/2005
3	Microvascular Rarefaction 10/2020 - 11/2015
3	Cardiovascular Diseases (Cardiovascular Disease) 10/2019 - 08/2014
3	Right Ventricular Hypertrophy 02/2014 - 09/2012
1	Cardiotoxicity 01/2022
1	Pulmonary Fibrosis (Fibrosing Alveolitis) 01/2022
1	Pneumothorax 11/2021
1	Lung Diseases (Lung Disease) 04/2021
1	Ulcer 01/2021
1	Hepatocellular Carcinoma (Hepatoma) 01/2021
1	Venous Thromboembolism 01/2021
1	Atrial Fibrillation 01/2021
1	Disease Progression 01/2021
1	Respiratory Tract Diseases (Respiratory Tract Disease) 12/2020
1	COVID-19 12/2020
1	Leukemia 01/2020
1	Dermatomyositis (Dermatopolymyositis) 02/2019
1	Hemorrhage 01/2019
1	Atrophy 01/2019
1	B-Cell Lymphoma (Lymphoma, B Cell) 08/2015

Drug/Important Bio-Agent (IBA)

15	MonocrotalineIBA 01/2022 - 09/2012
5	Proteins (Proteins, Gene)FDA Link 01/2022 - 08/2015
4	Pharmaceutical PreparationsIBA 10/2021 - 01/2015
4	Biomarkers (Surrogate Marker)IBA 10/2020 - 09/2012
4	MicroRNAs (MicroRNA)IBA 09/2015 - 08/2014
3	Therapeutic UsesIBA 01/2019 - 01/2013
3	Transcription Factors (Transcription Factor)IBA 01/2018 - 06/2014
3	Oxygen (Dioxygen)IBA 10/2017 - 10/2015
3	GoldIBA 01/2015 - 12/2012
3	Bosentan (Tracleer)FDA Link 03/2006 - 05/2005
2	STAT3 Transcription Factor (Signal Transducer and Activator of Transcription 3)IBA 01/2022 - 06/2014
2	Enhancer of Zeste Homolog 2 ProteinIBA 03/2021 - 10/2020
2	AnticoagulantsIBA 01/2021 - 01/2019
2	CrizotinibIBA 01/2021 - 01/2021
2	Long Noncoding RNAIBA 10/2020 - 11/2019
2	Oncogene Proteins (Oncogene Protein)IBA 01/2020 - 01/2013
2	apabetaloneIBA 01/2020 - 10/2019
2	Interleukin-6 (Interleukin 6)IBA 01/2019 - 01/2014
2	CalciumIBA 02/2017 - 11/2016
1	Thyroid Hormone-Binding ProteinsIBA 04/2022
1	Poly Adenosine Diphosphate RiboseIBA 04/2022
1	N- (1,2,3,5,6,7- hexahydro- S- indacen- 4- ylcarbamoyl)- 4- (2- hydroxy- 2- propanyl)- 2- furansulfonamideIBA 01/2022
1	Semaxinib (SU5416)IBA 01/2022
1	Atrial Natriuretic Factor (ANF)IBA 01/2022
1	prexasertibIBA 01/2022
1	InflammasomesIBA 01/2022
1	N'- (7- fluoroH- pyrrolo(1,2- a)quinoxalin- 4- yl)pyrazine- 2- carbohydrazideIBA 01/2022
1	Phosphotransferases (Kinase)IBA 01/2022
1	sulofenur (ISCU)IBA 10/2021
1	Antipsychotic Agents (Antipsychotics)IBA 03/2021
1	Trifluoperazine (Stelazine)FDA LinkGeneric 03/2021
1	DNA (Deoxyribonucleic Acid)IBA 01/2021
1	Estrogen ReceptorsIBA 01/2021
1	Yttrium-90IBA 01/2021
1	ApelinIBA 01/2021
1	pro-brain natriuretic peptide (1-76)IBA 10/2020
1	Phenylephrine (Neo-Synephrine)FDA LinkGeneric 10/2020
1	Brain Natriuretic Peptide (Natrecor)FDA Link 10/2020
1	E2F Transcription FactorsIBA 10/2020
1	CollagenIBA 01/2020
1	Pyruvate Dehydrogenase Acetyl-Transferring KinaseIBA 01/2020
1	Oxidoreductases (Dehydrogenase)IBA 01/2020
1	Pyruvic Acid (Pyruvate)IBA 01/2020
1	SGI 1776IBA 01/2020
1	Rubber (Elastica)IBA 01/2020
1	Amino Acyl-tRNA Synthetases (Aminoacyl-tRNA Synthetase)IBA 02/2019
1	Growth Differentiation Factor 15IBA 01/2019
1	Metformin (Glucophage)FDA LinkGeneric 01/2019
1	Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA 01/2019
1	Platelet Aggregation Inhibitors (Antiplatelet Drugs)IBA 01/2019
1	Checkpoint Kinase 1IBA 01/2019
1	Vitamin K FDA Link 01/2019
1	CCG 1423IBA 01/2018
1	LectinsIBA 01/2018
1	macitentanIBA 01/2018
1	Antineoplastic Agents (Antineoplastics)IBA 04/2017
1	mitochondrial calcium uniporterIBA 02/2017
1	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 01/2017
1	Histone Deacetylases (Histone Deacetylase)IBA 01/2017
1	potassium channel subfamily K member 3IBA 04/2016
1	Potassium Channels (Potassium Channel)IBA 10/2015
1	SurvivinIBA 08/2015
1	Epoprostenol (Prostacyclin)FDA LinkGeneric 01/2015

Therapy/Procedure

16	Therapeutics 10/2021 - 05/2005
2	Pneumonectomy (Lung Volume Reduction) 01/2011 - 06/2003
1	Chest Tubes (Chest Tube) 11/2021
1	Lung Transplantation 04/2021
1	Critical Care (Surgical Intensive Care) 12/2020
1	Intravenous Infusions 01/2015